Submitted by dcc on Thu, 2017-02-16 13:44 Study Title: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518; IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)CIRB: Pediatric CIRBLead Group: COGStatus: ActiveReview Status: Available to Open
